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ABSTRACT 
 
ANTI-CYTOMEGALOVIRUS ACTIVITY OF ATANYL BLUE PRL, AN 
ANTHRAQUINONE DERIVATIVE 
 
By Zohaib Alam, MS 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, July 2013 
 
Major Director: Michael McVoy, Ph.D. 
Professor, Department of Pediatrics and Microbiology and Immunology 
 
 
       Cytomegalovirus (CMV) is a significant cause of mortality and morbidity in 
immunocompromised patients and an important cause of birth defects if acquired in utero. The 
licensed CMV antivirals, ganciclovir, cidofovir and foscarnet, all target the viral DNA 
polymerase. For each drug prolonged use is associated with significant toxicities and 
development of drug resistance. None are approved for use during pregnancy. Therefore, 
development of new anti-CMV drugs that target different pathways would be beneficial. All 
herpesviruses encode an alkaline nuclease. That genetic disruption of the CMV alkaline 
nuclease, UL98, reduces CMV replication by 1,000-fold suggests that UL98 may be a useful 
target for development of novel anti-CMV drugs. Moreover, using herpes simplex virus type 1 
Hsiang and Ho found that the anthraquinone emodin inhibits activity of the viral alkaline 
nuclease, blocks viral replication in cell culture, and reduces viral pathogeneses in a mouse 
model (Brit. J. of Pharm., 2008). Earlier studies also showed that anthraquinone derivatives 
including emodin have anti-CMV activity (Barnard et al., Antiviral Research 1992 & 1995), 
although the mechanism of CMV inhibition has not been further studied. We therefore sought to 
confirm the anti-CMV activities of emodin and related anthraquinone derivatives, to characterize 
	  
	  
	   xi 
their mechanisms of action, and to determine specifically if they act through inhibition of UL98. 
Using a luciferase-based CMV yield reduction assay emodin inhibited CMV replication (IC50 = 
4.9 µM); however, that the TD50 for cytotoxicity (determined using an luciferase-based cell 
viability assay) was only 2-fold higher suggested that emodin may act non-specifically. Two 
additional anthraquinone derivatives (acid blue 40 and alizarin violet R) inhibited CMV only at 
high concentrations (IC50 = 238; 265 µM) that were also cytotoxic. Atanyl blue PRL, however, 
exhibited anti-CMV activity (IC50 = 6.3 µM) with low cytotoxicity (TD50 = 216 µM). Thus, 
characterization of atanyl blue PRL (impact on gene expression, GFP expression, viral spread, 
infectivity, time of addition studies, and inhibition of UL98 nuclease activity) should be 
informative. Atanyl blue PRL appears to block immediate-early gene expression and reduce 
early and late gene expression. Atanyl blue PRL also blocked GFP expression, reduced viral 
spread, and also lowered the infectivity of CMV. Finally, atanyl blue PRL inhibits UL98 alkaline 
nuclease activity at an IC50 of 5.7 µM. This suggests that atanyl blue PRL may inhibit CMV 
through inhibition of UL98. Thus, atanyl blue PRL represents a novel class of anti-herpesvirals 
and provides a lead structure for structure based drug discovery.  
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I. INTRODUCTION 
 
History of CMV 
Hippocrates documented an assortment of cutaneous lesions consistent with herpes 
simplex lesions. Greek scholars coined the term herpes, which means “to creep or crawl”, in 
reference to the spreading nature of herpetic lesions. Herpes viruses infect virtually all 
vertebrates and invertebrates and are one of the most common viruses found in humans (35). 
Cytomegalovirus, or CMV, belongs to the Herpesviridae family of viruses (1). 
The Herpesviridae family of viruses is a large family of double stranded DNA (120 to 235 kb) 
viruses. The DNA is encased in an icosahedral capsid and an outer protein matrix layer known as 
tegument (9). The Herpesviridae family is divided into three subfamilies: alphaherpesvirinae, 
betaherpesvirine, and gammaherpesvirinae. The alphaherpesvirinae are described as having rapid 
growth and spread in cell cultures. They infect fibroblasts and epithelial cells to replicate 
lytically and establish latency in sensory neurons. Examples of the alphaherpesvirinae are herpes 
simplex virus type 1 and type 2 (HSV-1, HSV-2) and varicella zoster virus. The 
betaherpesvirinae are characterized by slow infection and growth in cell culture and a long 
replication cycle. They can infect various cell types in lytic infection and can establish latency in 
lymphoid progenitor cells. Examples of the betaherpesvirinae are CMV, human herpesvirus 6, 
and human herpesvirus 7. The gammaherpesvirinae are known to have limited growth in 
lymphoblastoid cells and to establish latency in B or T cells. Examples of the 
gammaherpesvirinae are Epstien-Barr virus and Kaposi’s sarcoma-associated herpesvirus 
(KSHV) (35). 
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Molecular Biology of CMV 
CMV has a genome of 235 kb, the largest of any herpesvirus, encoding over 200 genes 
within a 100 nm diameter icosahedral capsid (10). The capsid is surrounded by a proteinaceous 
tegument, which is further surrounded by a glycoprotein and lipid bilayer envelope. The 
envelope is on the surface of the virus and contains glycoproteins such as gB, gN, gO, gH, gM, 
and gL. These glycoproteins function in virus-cell binding, cell fusion, virus entry into host cells, 
cell-to-cell spread, and virion maturation. Mutations in these glycoproteins can produce non-
infectious progeny virus (11).  
The CMV genome is expressed temporally in a regulated cascade leading to synthesis of 
three categories of viral proteins: Immediate-early, early, and late (figure 1). Immediate-early 
genes are the first viral genes to be expressed after a cell is infected and do not require the 
expression of other viral genes or proteins. Immediate-early gene products regulate the 
expression of early and late genes and the expression of early genes is dependent on the presence 
of immediate-early proteins. Early genes encode non-structural proteins such as viral DNA 
replication factors needed for DNA synthesis, DNA repair enzymes, and proteins involved in 
immune evasion. After the early proteins are synthesized viral DNA replication can occur. Late 
genes are only expressed after viral DNA synthesis begins. Late proteins are mainly involved in 
structural roles and the assembly and morphogenesis of the virion. The early and late proteins 
function together to allow the newly synthesized genomes to mature and package (11).  
 
CMV Life Cycle 
 
Virus attachment to the cell surface involves low affinity interaction of gB to heparin 
sulfate proteoglycans followed by a stronger binding of gB with its nonheparin receptor. The  
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Figure 1: Life Cycle of Herpesviruses: The virus enters the cell by attachment and penetration 
or endocytosis. Viral capsid and tegument proteins are released into the cytoplasm and the capsid 
is transported to the nucleus via microtubules. The viral capsid docks with the nucleopore and 
the viral dsDNA is released into the host nucleus. Immediate-early, early, and late gene 
expression and cytoplasmic translation of viral mRNA occur. Capsid proteins are transported to 
the nucleus from the cytoplasm and empty capsids are assembled. Viral DNA is packaged into 
the capsid and the capsid exits the nucleus, gains tegument, and gains its envelope as it exits the 
cell (21). Reprinted from Virus Research, 106/2, Mettenleiter TC, Budding events in herpesvirus 
morphogenesis, 167-180, Copyright (2004), with permission from Elsevier. 
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final interaction involves the fusion of the viral envelope with the cell membrane, allowing viral 
penetration (11). In some cell types such as endothelial and epithelial cells, viral entry occurs via 
endocytosis (36). After viral penetration, the capsid and tegument proteins are released into the 
cytoplasm and are translocated to the nucleus via microtubules (figure 1). The viral capsid docks 
with the nuclear pore and the viral dsDNA is released into the nucleus (37). Immediate-early, 
early, and late gene expression and cytoplasmic translation of viral mRNA occurs. Viral DNA 
circularizes in the nucleus. Replication of the circular viral DNA forms concatemeric DNA in the 
nucleus. Capsid proteins are transported to the nucleus and empty capsids are assembled. During 
the late stages of viral DNA replication concatemeric DNA is packaged into capsids and cleaved 
to unit length. The capsids acquire a primary envelope by budding at the inner nuclear membrane 
and followed by a de-envelopment at the outer nuclear membrane. The capsid now enters the 
cytoplasm and further matures by gaining tegument and the final glycoprotein-containing 
envelope as it buds into a vesicle (38). The vesicle is transported to the cell surface where it fuses 
with the cell membrane and mature progeny virus is released to the extracellular environment 
where it can infect more cells (figure 1) (13). 
 
 
Significance and Impact of CMV on Human Health 
 
CMV is a relatively common infection with seroprevalence of 60% or more in persons 
greater than 50 years of age. It is estimated that between 45 to 100% of women of reproductive 
age are seropositive for CMV. The portion of women who are seronegative for CMV are at risk 
of primary CMV infection during pregnancy and bear a risk of giving birth to babies who will 
suffer from CMV-related disabilities. Seroprevalence tends to be high in South America, Africa, 
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and Asia (>90%), and seroprevalence is also higher with non-whites and with individuals of 
lower socioeconomic status. Seroprevalence is almost 60% in United States and Europe. (2) 
 Most people infected with CMV are asymptomatic; however after primary infection some 
may show mild fever or mononucleosis-like symptoms and the host will remain infected with 
CMV in the latent phase for life. They may shed virus in urine, saliva, semen, cervical 
secretions, and breast milk and contact with these secretions can lead to transmission of CMV. 
For immunocompromised and immunosuppressed patients, CMV is a significant cause of 
mortality and morbidity. CMV is also an important cause of birth defects in newborns if acquired 
in utero. (39) 
 
CMV Infection and Disease Among Transplant Recipients 
CMV is a major cause of mortality and morbidity in patients undergoing stem cell and 
solid organ transplantation (40). Due to the opportunistic behavior under immunosuppression, 
CMV infection has a large impact on transplant recipients. Active CMV infection occurs in 30-
75% of transplant recipients and has a mortality rate of approximately 5%. The type of organ 
transplant has a role in acquiring CMV infection. Liver, lung, and pancreas transplant recipients 
have a high risk of acquiring CMV infection, whereas recipients of heart, small bowel, and 
kidney transplants have a lower risk (41). Disease results from viral invasion of organ systems or 
effects on the immune system that can increase the risk of other infections or promote acute graft 
rejection (40). Clinical manifestations of CMV are CMV pneumonia, gastrointestinal disease, 
hepatitis, CNS disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, CMV syndrome, 
and CMV-associated graft failure (3). Several diseases are linked to CMV infection with 
transplantation such as transplant rejection, transplant dysfunction, accelerated coronary 
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atherosclerosis after heart transplantation, vanishing bile duct syndrome following liver 
transplantation, constrictive bronchiolitis syndrome subsequent to lung transplantation, and the 
development of post-transplant lymphoproliferative disease (4). Severe disease is most prevalent 
when a seronegative recipient receives organs or blood products from a seropositive donor; this 
can lead to primary infection. However, for stem cell transplant recipients, the risks are reversed, 
severe disease is most prevalent when a seropositive recipient receives a stem cell transplant 
from a seronegative donor (51). CMV disease can also occur following reactivation of the virus 
from a latent state in seropositive transplant recipients. Furthermore, if the donor and recipient 
are both seropositive but with two distinct strains of CMV, then it can lead to a superinfection or 
reinfection of CMV (41).  
 
CMV in HIV-Infected Patients 
CMV is the most frequent opportunistic pathogen in patients infected with HIV. Upwards 
of 45% of patients with AIDS are afflicted with CMV disease at some point during the course of 
their AIDS disease.  CMV can affect the eyes, gastrointestinal tract, lungs, liver, and central 
nervous system, and can cause diseases such as retinitis, colitis, pneumonitis, hepatitis, and 
radiculopathy. CMV retinitis accounts for 85% of all CMV disease in patients with AIDS and 
untreated retinitis spreads through the retina and causes retinal destruction and blindness (5). 
Despite current therapies, most patients with CMV retinitis undergo relapse.  
 
Congenital and Perinatal CMV 
In the United States, 40,000 children or 1% of all live births are born with an active CMV 
congenital infection. However, only 8,000 or 20% of those births are symptomatic. CMV 
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infection is the most common congenital infection and a major cause of morbidity and mortality 
among infants (7). Infection can occur in utero or perinatally by transmission from mothers who 
are infected with primary CMV infection or have CMV reactivation. It can also occur after birth 
due to contact with secretions such as breast milk or saliva of a seropositive mother (18). In the 
United States, approximately 50% of women of childbearing age are seronegative and 
susceptible to primary CMV infection and up to 8% of seronegative mothers will become 
infected with CMV during pregnancy. Of those mothers who are infected during pregnancy, 50% 
will transmit CMV to their fetus, and approximately 28% of those fetuses will have symptoms at 
birth (8). However, if the mother is seropositive for CMV prior to pregnancy then the rate of 
infection of the fetus is 0.15 to 1.5%, displaying that prior maternal infection confers substantial 
protection against congenital infection and reduces the severity of disease (42). Symptomatic 
children may have mental retardation, cerebral palsy, sensorineural hearing loss, impaired vision, 
microcephaly, encephalopathy, seizures, chorioretinitis, and hepatosplenomegaly (43). Hearing 
loss occurs in approximately 40% of symptomatic infants with congenital CMV infection (43). 
Fifteen-percent of infants with asymptomatic congenital CMV infection at birth will later 
develop hearing loss (44). 
 
CMV Antivirals 
Currently there are several drugs approved for the treatment of CMV infections: 
Ganciclovir and its prodrug Valganciclovir, Foscarnet, Cidofovir, Acyclovir and its prodrug 
Valacyclovir, and Fomivirsen (shown in figure 2). Ganciclovir and its prodrug Valganciclovir, 
Foscarnet, Cidofovir are approved for systemic CMV treatment. Valacyclovir is approved for 
prophylaxis of renal transplant recipients and other solid organ transplants (outside  
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Figure 2: Current antivirals used for treating CMV infections: Guanine and cytidine 
nucleosides are shown on top with ganciclovir, valganciclovir, acyclovir, valacyclovir, foscarnet 
and cidofovir also shown. 
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the United States). Fomivirsen is approved for local treatment of CMV retinitis. Unfortunately 
these therapies are inadequate. They can show significant toxicities and limited efficacy. 
Furthermore, due to their potential toxicities, none are approved for congenital use. They can 
also be limited by a low percentage of the drug reaching systemic circulation and a risk of drug 
resistance with prolonged use (13). With the exception of fomiversen, all approved drugs target 
the viral DNA polymerase, so there is likelihood that mutations in the DNA polymerase may 
render these drugs ineffective (13).  
 
Ganciclovir and Valganciclovir 
 Ganciclovir, also known as DHPG (9-(1,3-dihydroxy-2-propoxymethyl)guanine), was the 
first antiviral approved for use against CMV and continues to be the drug-of-choice for CMV 
infection and CMV disease in transplant recipients. Approved in 1989, Ganciclovir is a 
nucleoside analog of 2-deoxyguanosine and is marketed under the names Cytovene, Cymevene, 
and Vitrasert. Ganciclovir is first phosphorylated by the viral kinase UL97 to its monophosphate 
form (figure 3). After the initial phosphorylation by the viral kinase it is further phosphorylated 
to its diphosphate form then triphosphate form by host cell kinases (figure 3). The triphosphate 
form of ganciclovir competes with deoxyguanosine triphosphate (dGTP)  incorporation during 
new viral DNA synthesis by the viral DNA polymerase (UL54) (figure 3). The incorporation of 
ganciclovir inhibits the addition of dGTP into the viral DNA and the synthesis of the viral DNA 
is markedly diminished (13, 45). Mutations in UL97 or UL54 can lead to resistance to 
ganciclovir (14). UL97 mutations generally emerge first and confer a lower level of resistance in 
comparison to UL54 mutations, which emerge later and have a higher level of drug resistance 
(16). Ganciclovir has a low oral bioavailability (~5-6%)  
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Figure 3: Mechanism of action of ganciclovir, cidofovir, and foscarnet: Ganciclovir is a 
nucleoside analog of 2-deoxyguanosine. Ganciclovir is first phosphorylated by the viral kinase 
UL97 to its monophosphate form. After the initial phosphorylation by the viral kinase it is 
further phosphorylated to its diphosphate form then triphosphate form by host cell kinases. The 
triphosphate form of ganciclovir competes with dGTP  incorporation during new viral DNA 
synthesis by the viral DNA polymerase (UL54). The incorporation of ganciclovir triphosphate 
inhibits the addition of dGTP into the viral DNA. Cidofovir is an acyclic nucleoside 
phosphonate. This nucleoside analog inhibits chain elongation by inhibiting the incorporation of 
dCTP in to the nascent viral DNA. Cidofovir is a monophosphate that is converted to the active 
diphosphate form by host cell kinases. Cidofovir diphosphate acts as a competitive inhibitor to 
dCTP and incorporates into the viral DNA blocking the function of the viral DNA polymerase 
leading to premature chain termination of viral DNA synthesis. Foscarnet inhibits the function of 
the viral DNA polymerase by binding to the pyrophosphate binding site and inhibiting the 
release of pyrophosphate from the terminal nucleoside triphosphate on the growing DNA chain. 
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however its prodrug, valganciclovir, has a much higher oral bioavailability (~60%).  
Valganciclovir is a L-valyl ester of ganciclovir and is converted to ganciclovir by intestinal and 
hepatic esterases (15).  
Ganciclovir is used to treat CMV retinitis in AIDS patients, prevention of CMV disease 
in solid organ and heart and bone marrow transplant patients, and prevention of CMV infection 
in advanced HIV patients who are at risk for CMV disease (13).  
Ganciclovir is associated with hematologic side affects such as neutropenia, anemia, and 
thrombocytopenia. It is also associated with reproductive toxicity and aspermatogenesis. 
Ganciclovir is also classified as a potential human carcinogen, teratogen, and mutagen. These 
toxicities and the potential for drug resistance to ganciclovir limit the therapeutic usefulness of 
ganciclovir. Furthermore, ganciclovir is not approved for the treatment of congenital CMV 
infections (13). 
   
Foscarnet 
Foscarnet, also known as phosphonoformic acid, was the second drug approved for use 
against CMV infections. Foscarnet is generally considered a second-line therapy for the 
treatment of CMV infections, however, it is the preferred drug for patients who have ganciclovir 
resistance or have dose-limiting neutropenia. Approved in 1991, foscarnet is a pyrophosphate 
analog and is marketed under the name Foscavir. Foscarnet inhibits the function of the viral 
DNA polymerase by binding to the pyrophosphate binding site and inhibiting the release of 
pyrophosphate from the terminal nucleoside triphosphate on the growing DNA chain (figure 3). 
Unlike ganciclovir, foscarnet  does not require host or viral kinases to function, however, simiilar 
to ganciclovir, resistance mutations map to UL54. Further, cross-resistance has also been seen 
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between ganciclovir and Foscarnet. Foscarnet is mainly used for treatment of CMV retinitis in 
patients with HIV infection. However, foscarnet is associated with nephrotoxicity and electrolyte 
imbalance that may cause cardiac or neurological disorders and even death. (13). Foscarnet has 
an oral bioavailability of 12-22% and is not approved for use with congenital CMV infections 
(13, 17).  
 
Cidofovir 
Cidofovir, also known as 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl] cytosine 
dihydrate, was the third drug approved for use against CMV disease. Cidofovir is a broad-
spectrum antiviral drug that can be used against other herpesviruses and other DNA viruses such 
as the smallpox virus. Approved for use against CMV in 1996, cidofovir is an acyclic nucleoside 
phosphonate and is marketed under the name Vistide. Cidofovir is a monophosphate that is 
converted to the active diphosphate form by host cell kinases. Cidofovir diphosphate acts as a 
competitive inhibitor to dCTP and incorporates into the viral DNA, blocking the function of the 
viral DNA polymerase leading to premature chain termination of viral DNA synthesis. Unlike 
ganciclovir, cidofovir does not need the viral kinase UL97 for the first phosphorylation. 
However, like ganciclovir, mutations in the viral DNA polymerase gene UL54 can lead to 
resistance to cidofovir. Cidofovir is mainly used for the treatment of CMV retinitis in AIDS 
patients and can also be used in patients who have developed a resistance to ganciclovir due to 
UL97 mutations. It can also be used with transplant patients.  However, cidofovir is associated 
with significant nephrotoxicity and neutropenia and is also classified as a potential human 
carcinogen and teratogen (13). Cidofovir has an oral bioavailability of less than 5% and is not 
approved for use with congenital CMV infections (13, 17).  
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Acyclovir and Valacyclovir 
Acyclovir, also known as acycloguanosine or acyclovir, is another antiviral drug that can 
be used against CMV infections. Like ganciclovir, acyclovir is an analog of 2’-deoxyguanosine 
and is marketed under the names Cyclovir, Herpex, Acivir, Acivirax, Zovirax, Zoral, and Xovir.  
Also like ganciclovir, acyclovir is first phosphorylated by the viral kinase UL97 to its 
monophosphate form. After the initial phosphorylation by the viral kinase it is further 
phosphorylated to its diphosphate form then its active triphosphate form by the host cell kinases. 
The triphosphate form of acyclovir leads to chain termination during new viral DNA synthesis 
by UL54. The incorporation of acyclovir inhibits the addition of dGTP into the viral DNA and 
the synthesis of the viral DNA is inhibited. Further, like ganciclovir, mutations in UL97 or UL54 
can lead to resistance to acyclovir. However, unlike ganciclovir, acyclovir is a less efficient 
substrate for host cell kinases leading to less potency, lower intracellular concentrations, and 
lower toxicity. Acylclovir has a low bioavailability (~6-10%), however its prodrug, valacyclovir 
has a considerably higher oral bioavailability (55%). (13). Valacylclovir is the L-valyl ester of 
acyclovir and is converted to acyclovir by hepatic esterases (15). 
Acyclovir is not approved for use with CMV disease, however it is a very potent drug 
against some viruses. It gained approval in 1982 and is commonly used in the treatment of HSV 
and varicella zoster infections. It is also used with transplant patients to prevent the HSV 
reactivation and can also be used with neonatal HSV infections (13). Acyclovir has been safely 
used in pregnant women to reduce active genital lesions and transmission to newborns (13).  
Even though acyclovir has limited efficacy against some herpesviruses such as Epstein-
Barr virus and CMV, the use of acyclovir against CMV disease has been studied (19). When 
acyclovir was used in solid organ transplant patients, a 56% reduction in CMV infection and a 
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59% reduction in CMV disease was seen in comparison to patients receiving placebo or no 
therapy. Similar results were seen with valacyclovir. In Europe, Valacyclovir is approved for use 
against CMV infection and disease in renal, heart, and solid organ transplant patients (13).  
 
Fomivirsen 
 Fomivirsen is another antiviral drug that is used against CMV infection. It is the first anti-
sense antiviral to be approved by the FDA (20). Fomivirsen is a 21-nucleotide anti-sense RNA 
with the sequence 5’-GCG-TTT-GCT-CTT-CTT-GCG-3’. Approved in 1998, it is marketed 
under the name Vitravene. Fomivirsen is complementary to the mRNA sequence of CMV 
immediate-early-2 gene (IE2); hence it specifically targets the immediate-early transcriptional 
unit of CMV. Fomivirsen is mainly used as a second-line therapy for treatment of CMV retinitis 
in AIDS patients who are resistant to ganciclovir or have dose-limiting adverse reactions to 
ganciclovir. Fomivirsen is not used systemically; rather it is used locally by the administration of 
an intraocular injection one to two times every four weeks. The most common adverse effect is 
an ocular inflammation known as uveitis, however it can be treated by topical corticosteroids 
(13).  
 
UL98 
 Alkaline nucleases are highly conserved throughout the Herpesvirus family (50). The 
protein UL98 is an alkaline nuclease encoded by the UL98 gene of CMV and has both 
endonuclease and exonuclease activity; however the function of alkaline nucleases are not fully 
understood (50). Alkaline nucleases have optimal nuclease activity at alkaline pH environments 
(50). Alkaline nucleases may also be involved in viral DNA processing and capsid egress from 
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the nucleus (29). It has been previously described that emodin specifically inhibits the activity of 
HSV-1 alkaline nuclease, UL12. Emodin treatment of HSV infected cells results in accumulation 
of capsids in the nucleus (22). Further, it has been shown that CMV UL98 null mutants are 
viable. However, viral replication was reduced by up to 1,000-fold, indicting UL98 is an 
important though not essential CMV gene (50). Due to the need for CMV antivirals with 
alternative targets of action and lower toxicity, investigation of UL98 could lead to a novel target 
for the development of new CMV antivirals.  
 
Objectives 
 Current therapy against cytomegalovirus is sub-optimal. Antiviral drugs have incomplete 
effectiveness against CMV infections and substantial dose-limiting toxicities with prolonged use. 
None are approved to for use with congenital infections, and patients develop resistance to the 
drugs. Further, the most commonly used drugs act by inhibiting the viral DNA polymerase, so 
there is a chance of cross-resistance of drugs. Countless children develop permanent disabilities 
and many children and adults die each year because there are no other options for the treatment 
of their CMV disease.  
Therefore, we seek to study new drugs and drug targets that can be used against CMV. 
New drugs would give more options for those suffering with CMV disease. A new drug target 
could open up an entire new area of antiviral research and development of a new class of CMV 
drugs, especially for patients resistant to current therapy. New drugs could also be used 
synergistically with current therapies to improve effectiveness. Novel drugs might also have 
lower toxicity and be safe to use with congenital infections. It has been previously reported that 
anthraquinone derivatives have antiviral activity against herpes simplex and CMV, however the 
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mechanism of this action is uncertain (23, 24). We have evaluated anthraquinone derivatives 
emodin, atanyl blue PRL (also known as acid blue 129), acid blue 40, and alizarin violet R in this 
study.  
 
Anthraquinones 
Anthraquinone, also known as anthracenedione or dioxoanthracene, is an aromatic 
organic compound with the chemical formula C14H8O2 (figure 4). Anthraquinone derivatives 
have this general structure, but may have various substituents on C-1, C-2, C-3, C-4, C-5, C-6, 
C-7, and C-8. Synthetic dyes are often derived from anthraquinones (25). Anthraquinones can be 
used for the industrial production of hydrogen peroxide and also as a laxative (26, 27). 
Anthraquinones are present in many plants extracts such as Rheum officinale, Aloe barbadensis, 
Rhamnus frangula, Rhamnus purshianus, Cassia angustifolia, Hypericum perforatum, and 
Polygonum genera (22, 28). As discussed further below, anthraquinones have been shown to be 
directly virucidal to certain enveloped and RNA and DNA viruses (28). 
 
Antiviral activity of Anthraquinone Derivatives 
The antiviral activity of anthraquinone derivatives has been investigated. In 1951, it was 
reported that hypericin, an anthraquinone dimer isolated from the plant Hypericum perforatum, 
has both antiviral and virucidal activity (32). Synthetic derivatives of anthraquinone can also 
have in vivo antiviral activity against picornavirus encephalomyocarditis (EMC) virus in mice 
(33). In 1979, it was reported that a hypericin-containing topical ointment helped in the healing 
of herpes simplex infections (32). It is also reported that hypericin inhibited the replication of 
influenza virus A and B, both in vitro and in vivo, and herpes simplex virus in vitro (32).   
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Figure 4: Chemical structure of Anthraquinone (9,10-dioxoanthracene): Anthraquinone 
derivatives have this general structure, but may have various substituents on C-1, C-2, C-3, C-4, 
C-5, C-6, C-7, and C-8. The numbering system is not consistent with Chemical Abstracts or with 
IUPAC nomenclature; it is shown this way for ease of comparison with derivatives. (24) 
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In addition, it has been reported that hypericin has activity against murine retroviruses and 
Moloney murine leukemia virus (32). Anthraquinones and their derivatives have demonstrated 
activity against human immunodeficiency virus (HIV) and other retroviruses, herpes simplex 
virus type 1 and type 2, influenza virus, vesicular stomatitis virus, Epstein-Barr virus, Murine 
Friend leukemia virus, and poliovirus (23, 24, 32, 33). It has also been shown that aloe emodin, 
an anthraquinone prepared from Aloe vera, is able to inhibit HSV-1 and HSV-2 in vitro and in 
vivo (33, 34). Relevant to our interest in CMV UL98 as a potential antiviral target, emodin was 
also shown to inhibit enzymatic activity of the HSV-1, alkaline nuclease, UL12, in vitro. 
Moreover, in 1992 anthraquinone derivatives were studied for antiviral activity against CMV 
(24). Several anthraquinone derivatives showed activity against CMV, including emodin, atanyl 
Blue PRL, acid blue 40, and alizarin violet R (23, 24). Their half-maximal inhibitory 
concentrations  (IC50) were 4.1 µM, 7 µM, 10 µM, and 10 µM respectively (23, 24). 
  
Summary 
Since most of the currently approved antiviral therapies against CMV target the viral 
DNA polymerase, there is a high chance of drug resistance with prolonged use. Additionally, 
these drugs are associated with significant dose-limiting toxicities such as neutropenia and 
nephrotoxicity. Therefore, there is a substantial need for alternative anti-CMV compounds with 
novel, non-nucleoside targets of inhibition which are also less toxic to the patients. Having non-
nucleoside drugs with a different mechanism of action than the current antivirals may allow the 
treatment of congenital infections, give patients more options for treatment, and most 
importantly, it could save the lifes of countless adults and children. Understanding and 
	  
	  
	   19 
identifying the mechanism of action of anthraquinone derivatives may allow us to identify a 
novel target of inhibition against CMV. 
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Figure 5: Chemical Structure of Anthraquinone derivatives used in this study: Emodin, 
atanyl blue PRL (also known as acid blue 129), acid blue 40, and alizarin violet R are shown. 
The numbering system is not consistent with Chemical Abstracts or with IUPAC nomenclature; 
it is shown this way for ease of comparison with derivatives. (23).  
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II. MATERIALS AND METHODS 
 
Cells 
Human fetal lung fibroblast (MRC-5) cells (ATCC CCL-171) were obtained from 
American Type Culture Collection (ATCC). MRC-5 cells were grown in minimum essential 
medium (Gibco-BRL) supplemented with 10% fetal calf serum (HyClone Laboratories), 10,000 
IU/ml penicillin, 10 mg/ml streptomycin, and 29.2mg/ml L-glutamine (Gibco-BRL) (MEM). All 
cell cultures were maintained at 37°C in a 5% carbon dioxide (CO2) atmosphere. 
 
Viruses 
CMV strain BADrUL131-Y4 was a gift from Dai Wang and Thomas Shank. It was 
derived from a BAC clone of the CMV strain AD169 genome that had been modified in E.coli 
by Wang and Shenk to contain a green fluorescent protein reporter cassette for efficient detection 
and quantification of viral infection (46). Subsequently the UL131 mutation was repaired to 
express a functional UL131 protein that allows efficient entry and replication in both MRC-5 
cells and ARPE-19 epithelial cells (47). Strain RC2626 is a Towne strain CMV. A luciferase 
expression cassette was introduced into the US2-US6 region to create recombinant virus RC2626 
(48). Due to mutation in UL130, RC2626 can replicate efficiently in fibroblasts but not in 
epithelial cells. 
 
Drugs 
Ganciclovir was purchased from InvivoGen. Fifteen potential UL98 inhibitors were 
acquired from the Synthesis and Chemistry Branch, Developmental Therapeutics Program, 
Division of Cancer Treatment and Diagnosis, National Cancer Institute. Emodin, atanyl blue 
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PRL and acid blue 40 were purchased from Sigma-Aldrich Co., and alizarin violet R was 
purchased from MP Biomedicals. To produce stock solutions, ganciclovir was solubilized in 
water at a concentration of 100 mM. Emodin, atanyl blue PRL, acid blue 40, and alizarin violet 
R were dissolved in dimethyl sulfoxide (Sigma-Aldrich company) at a stock concentration of 
100 mM. The potential UL98 inhibitors were dissolved in dimethyl sulfoxide at a stock 
concentration of 10 mM. The compounds were stored at -20 degrees Celsius.  
 
Luciferase Reporter Gene Assay for Anti-Cytomegalovirus Activity (Protocol based on an 
assay developed by Bhave et al. (2013), Antiviral Research in press) 
Clear-walled, clear-bottom 96-well plates containing confluent monolayers of MRC-5 
cells were infected with RC2626 virus at a multiplicity of infection (MOI, ratio of infectious 
virus to cell) of 0.03 and incubated for 1 hour to allow viral entry. Eleven two-fold serial 
dilutions of emodin and six three-fold dilutions of atanyl blue PRL, acid blue 40, or alizarin 
violet R were prepared in 200 µl MEM in triplicate in a 96-well format. These compound 
dilutions were transferred to infected cells to produce final drug concentrations of 0.24 to 250 
µM for emodin and 1.03 to 250 µM for atanyl blue PRL, acid blue 40, and alizarin violet R. 
UL98 inhibitor compounds were also prepared in 200 µl MEM in triplicate in a 96-well format 
and used at 25 µM and 100 µM final concentrations. Triplicates of no drug, no virus, and 
ganciclovir controls were included on each plate. 
After incubation for 5 days, 50 µl supernatants from the 96-well plate above were 
transferred to a black-walled, clear-bottom 96-well plate containing confluent MRC-5 
monolayers. After 24 hours, 100 µl Steady-Glo luciferase assay reagent (Promega) was added. 
After allowing 10 minutes for the luciferase assay reagent to lyse the cells, the luciferase activity 
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was measured in relative light units (RLU) using Biotek Synergy HT Multimode Microplate 
Reader. To allow easier comparability between experiments, the data were normalized by 
converting RLU to “percent maximum luminescence” for each experiment. The data were fitted 
with a nonlinear variable slope four-parameter regression curve and the half-maximal inhibitory 
concentrations  (IC50) (drug concentrations at which luciferase signal was reduced by half) of the 
test compounds were determined using Prism software by GraphPad, Inc.  
 
Luciferase-Based Toxicity Assay 
Black-walled, clear bottom 96-well plates containing confluent monolayers of MRC-5 
cells were incubated with eleven two-fold serial dilutions of emodin or six three-fold dilutions of 
atanyl blue PRL, acid blue 40, or alizarin violet R were prepared in 200 µl MEM in triplicate in a 
96-well format. These compound dilutions were transferred to cells to produce final drug 
concentrations of 0.24 µM to 250 µM for emodin or 8.23 µM to 2000 µM for atanyl blue PRL, 
acid blue 40, and alizarin violet R. Triplicates of no drug and no cell controls were included on 
each plate. 
After incubation for 5 days, 100 µl of supernatants were removed and 100 µl CellTiter-
Glo assay reagent (Promega) was added to each well. Luminescence was measured in RLU’s 
using Biotek Synergy HT Multimode Microplate reader and was normalized to “percent 
maximum luminescence” for easier comparability between experiments. The data were fitted 
with a nonlinear variable slope four-parameter regression curve and the median toxic dose  
(TD50) (compound concentration at which luminescence signal was reduced by half) of the 
compounds was determined using Prism software by GraphPad, Inc. 
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GFP-Based Assay of Entry and GFP Expression 
Clear-walled, clear-bottom 96-well plates containing confluent monolayers of MRC-5 
cells were infected with BADrUL131-Y4 at 10,000 pfu (plaque forming units) per well 
(MOI=1). Six three-fold dilutions of atanyl blue PRL were prepared in 200 µl MEM in 
quadruplicate in a 96-well format. The atanyl blue PRL dilutions were transferred to cells 
immediately after virus infection to produce final compound concentrations of 1.03 to 250 µM. 
Photomicrographs of GFP fluorescence were taken every two days using a Nikon Eclipse TS100 
inverted microscope and GFP fluorescence was quantitated using a Biotek Synergy HT 
Multimode Microplate Reader. The data were normalized by converting RLU’s to “percent 
maximum fluorescence” for each experiment. The data were fitted with a nonlinear variable 
slope four-parameter regression curve and the half-maximal inhibitory concentrations  (IC50) 
(drug concentrations at which fluorescence signal was reduced by half) of the compounds were 
determined using Prism software by GraphPad, Inc. Photomicrographs were organized by day 
and concentration of compound using Illustrator by Adobe Systems Incorporated. 
 
GFP-Based Assay of Viral Spread 
Clear walled, clear bottom 96-well plates containing confluent monolayers of MRC-5 
cells were infected with BADrUL131-Y4 at 1,000 pfu (MOI=0.1) or 100 pfu (MOI=0.01) per 
well. Six three-fold dilutions of atanyl blue PRL were prepared in 200 µl MEM in quadruplicate 
in a 96-well format. The atanyl blue PRL dilutions were transferred to cells immediately after 
virus infection to produce final compound concentration of 1.03 to 250 µM. Every two days, 
photomicrographs of GFP fluorescence were taken using a Nikon Eclipse TS100 inverted 
microscope and RLU’s were measured using Biotek Synergy HT Multimode Microplate Reader. 
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The data were normalized by converting RLU’s to “percent maximum fluorescence” for each 
experiment. The data from the 1,000 pfu per well infection were fitted with a nonlinear variable 
slope four-parameter regression curve and the IC50 (drug concentrations at which fluorescence 
signal was reduced by half) of the compounds were determined using Prism software by 
GraphPad, Inc. Using the photomicrographs from the 100 pfu per well infection, a single 
infected cell was examined over time for viral spread and growth to neighboring cells. 
Photomicrographs were organized by day and concentration of compound using Illustrator by 
Adobe Systems Incorporated. 
 
GFP-Based Infectivity Assay for Susceptibility of CMV to Atanyl Blue PRL 
Two clear-walled, clear-bottom 96-well plates containing confluent monolayers of MRC-
5 cells were infected with BADrUL131-Y4 (MOI=0.01). Five three-fold dilutions of atanyl blue 
PRL were prepared in 200 µl MEM. These compound dilutions were transferred to infected cells 
with 32 wells for each dilution to produce final drug concentrations of 3.09 µM to 250 µM. 32 
wells of no drug control were also included on the plate. After incubation for 14 days, each of the 
six sets of 32 wells was counted for the presence or lack of green fluorescence using a Nikon 
Eclipse TS100 inverted microscope. The presence of fluorescence indicated a positive well. The 
number of positive wells out of 32 was converted to “percent positive wells” and was fitted with 
a nonlinear variable slope four-parameter regression curve and the IC50 (amount of compound 
concentration at which 50% of no drug control were positive for fluorescence) of the compounds 
was determined using Prism software by GraphPad, Inc. 
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Time of Addition Assay 
 Clear-walled, clear-bottom 96-well plates containing confluent monolayers of MRC-5 
cells were infected with RC2626 virus (MOI=0.03). Atanyl blue PRL was prepared at a 
concentration of 27.8 µM in 200 µl MEM and added in triplicates at 0 hours, 1 hour, 6 hours, 12 
hours, 24 hours, 48 hours, 72 hours, 96 hours, or 120 hours post infection. Triplicates of 
ganciclovir (10 µM), BAY 38-4766 (8 µM), no drug, and no virus were also included on the 
plate. In a second group triplicate samples of RC2626 were incubated with atanyl blue PRL at 
27.8 µM for 1 hour followed by 10-fold dilution with culture medium. Then added to cells 
(MOI=0.03).  
After incubation for 5 days, 50 µl supernatants from the 96-well plate were transferred to 
a black-walled, clear-bottom 96-well plate containing confluent MRC-5 monolayers. After 24 
hours, 100 µl Steady-Glo luciferase assay reagent (Promega Corporation) was added. After 
allowing 10 minutes for the luciferase assay reagent to lyse the cells, the luciferase activity was 
measured in relative light units (RLU’s) using Biotek Synergy HT Multimode Microplate 
Reader. To allow easier comparability between experiments, the data was normalized by 
converting RLU’s to “percent maximum luminescence” for each experiment. In order to 
visualize the effect of the compound when added at different times after infection, percent 
maximum luminescence was plotted as a function of time using Prism software by GraphPad, 
Inc. 
 
Western Immunoblot Analysis Assay 
 T25 flasks (Corning) containing confluent MRC-5 cells were infected with BadrUL131-
Y4 at 8x10e5 pfu/flask (MOI=0.8). Compounds were added immediately after infection and cells 
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were harvested after 24, 48, 72, and 96 hours along with untreated cultures at the same time 
points and a non-infected control. Whole cell lysates were collected by scraping into media and 
pelleted by centrifugation for 5 minutes at 2000 rpm. Pelleted cells were lysed in Laemmli buffer 
(Bio-Rad) and beta-mercaptoethanol was added. Lysates were vortexed, heated to 95 degrees 
Celsius for 5 minutes, then centrifuged for 3 minutes at 6000 rpm. Supernatants were aliquoted 
and stored at -20 degrees Celsius. Prior to loading on the gel lysates were heated to 95 degrees 
Celsius for 5 minutes. Lysates were separated on 10-20% Criterion Tris-HCl polyacrylamide 
gels (Bio-Rad) at 100 volts for 2 hours in a 1x Tris/glycine/SDS running buffer (Bio-Rad). 
Separated proteins were transferred to 0.4 µm nitrocellulose membranes (Bio-Rad) at 0.42 amps 
for 2 hours in a 10% 10X Tris/glycine (Bio-Rad) and 20% methanol transfer buffer. Membranes 
were blocked for 1 hour in phosphate buffered saline (PBS), 0.02% Tween-20 (Fisher), and 5% 
powered milk. Primary antibodies used were anti-cytomegalovirus mouse monoclonal antibody 
to UL98 (I-2-gift from Jay Nelson), mouse monoclonal to UL99 (Goodwin Institute), mouse 
monoclonal antibody to IE1/2 mAB810 (Millipore), and rabbit polyclonal antibody to 
glycoprotein B (Vical) and were diluted in blocking buffer at 1:1000, 1:1000, 1:500, and 1:2000 
dilutions respectively. Membranes were incubated with primary antibody at 4 degrees Celsius 
overnight. Membranes were washed every 5 minutes for 30 minutes with a 0.02% Tween-
20/PBS wash buffer. Secondary antibodies used were horseradish peroxidase (HRP)-conjugated 
goat anti-mouse antibody (Thermo-Fisher) used for mouse primary antibodies and goat anti-
rabbit antibody (Thermo-Fisher) used for rabbit primary antibodies. Secondary antibodies were 
diluted in blocking buffer at 1:5000 dilution and incubated for 1 hour at room temperature with 
agitation on a rocker. The membranes were washed every 5 minutes for 30 minutes and 
incubated for 5 minutes with enhanced chemiluminescence western blotting substrate (Thermo-
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Fisher). Chemiluminescence was detected by exposure of X-ray film (Thermo-Fisher) at various 
times of exposure and processed using Kodak X-Omat 1000A processor. 
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III. RESULTS 
 
A. Evaluation of Potential UL98 Inhibitor Compounds 
1. Introduction 
The protein UL98 is an alkaline nuclease encoded by the UL98 gene of CMV. 
Herpesvirus alkaline nucleases have exonuclease and endonuclease activity and may be 
involved in viral DNA processing and capsid egress from the nucleus (29).  It has been 
shown that UL98 null mutants are viable; however, viral replication is attenuated by up to 
1,000-fold, indicted that while UL98 is not an essential CMV gene, it is highly important 
for efficient replication (50). Due to the importance of UL98 in CMV replication, 
investigation of UL98 could lead to a novel target for the development of new CMV 
antivirals.  
Our collaborators Hardik Parikh and Glenn Kellogg (VCU Institute for Structural 
Biology and Drug Discovery) used the amino acid sequence of CMV UL98 alkaline 
nuclease (strain AD169) to identify a template structure based on a model structure for 
UL98 could be built. The Shutoff and Exonuclease Protein (SOX) from Kaposi’s 
sarcoma-associated herpesvirus (KSHV) was chosen as the template structure for the 
model building of CMV UL98. The amino acid sequence of UL98 was aligned to the 
sequence of KSHV-SOX, and the active site and 5’ phosphate binding residues in UL98 
alkaline nuclease were identified based on their alignment with the corresponding 
residues in KSHV-SOX. The predicted active site amino acids R164, S252, D254, E278, 
and K280, are shown in figure 6. A homology model of UL98 alkaline nuclease was built 
based on the crystal structure of KSHV-SOX and the sequence alignment. A model was  
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Figure 6: Active site residues of UL98 alkaline nuclease. The predicted active site 
amino acids of CMV UL98 alkaline nuclease shown are R164, S252, D254, E278, and 
K280. Figure courtesy of Hardik Parikh and Glenn Kellogg.  
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selected based on its ability to accommodate a DNA fragment in the active site as well as 
satisfying spatial, carbon-carbon and nitrogen-oxygen distance, and bond angle 
constrains (50). The UL98 alkaline nuclease-double stranded DNA complex was used to 
identify important molecular interactions in that association, which allowed a model to be 
generated that showed desirable ligands that might bind at the active site of UL98 and 
inhibit its activity. A 3-dimensional model was created that was used to perform a virtual 
screening of the National Cancer Institute Open Database of over 250,000 compounds in 
order to find potential UL98 inhibitor compounds. Each potential UL98 inhibitor 
compound was docked, in silico, to the UL98 alkaline nuclease active site model and 
ranked based on binding free energy. The compounds were also analyzed visually to 
verify reasonable binding in the active site such that the catalytically important residues 
would be involved. Using this procedure, our collaborators were able to use the 
homology model of UL98 to conduct a virtual screening to identify potential inhibitors of 
UL98’s alkaline nuclease activity; the 15 compounds most likely to inhibit UL98 activity 
are shown in figure 7. 
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Figure 7: Top 15 compounds most likely to inhibit UL98 alkaline nuclease activity. 
Compound structures shown above are the 15 compounds from the National Cancer 
Institute Open Database compounds that are most likely to inhibit UL98 alkaline nuclease 
activity based on in silico screening. Unpublished data courtesy of Hardik Parikh and 
Glenn Kellogg.  
	  
	  
	   33 
2. Results 
In order to investigate the antiviral activity of the 15 potential UL98 inhibitor 
compounds from the National Cancer Institute, 96-well plates containing MRC-5 cells 
were infected with RC2626 virus incubated for one hour. Potential UL98 inhibitors were 
added at 25 µM and 100 µM final concentrations. After incubation for five days, the 
amount of infectious virus in the culture supernatants was measured by transferring 50 µl 
of supernatants to a black-walled, clear-bottom 96-well plate containing MRC-5 
monolayers. After 24 hours, luciferase activity was measured.  
Figure 8 shows the luminescence of the 15 potential UL98 inhibitor compounds at 
100 µM concentration. Also shown are the no-drug, no-virus, and ganciclovir controls. 
The 15 compounds displayed a luciferase signal of approximately 60,000 to 70,000, 
which was very similar to the no-drug control. The ganciclovir control reduced the 
luciferase signal down to almost the same level as the no-virus control.  
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Figure 8: Luciferase-based antiviral activity of 15 potential UL98 inhibitors from 
National Cancer Institute. Confluent MRC-5 monolayers in 96-well plates were 
infected with RC2626 (MOI = 0.03) and incubated for 5 days in the presence of different 
compounds at a concentration of 100 µΜ. Supernatants were transferred to another 96-
well plate with MRC5 monolayers, incubated for 24 hours, and luciferase signal was 
measured. 
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3. Conclusions 
The 15 potential UL98 inhibitor compounds did not significantly reduce the 
luciferase signal even at a very high concentration of 100 µΜ, suggesting that the 
compounds did not have any antiviral activity. However, these compounds may still have 
activity against UL98 alkaline nuclease but were unable to cross the cell membrane, and 
therefore were unable to exhibit antiviral activity. An evaluation of activity against UL98 
nuclease activity in vitro is planned which will address the concern of the potential UL98 
inhibitor compounds being unable to cross the cell membrane. 
 
B. Evaluation of Emodin, Atanyl Blue PRL, Acid Blue 40, and Alizarin Violet R 
1. Introduction 
Anthraquinones are aromatic organic compounds with the chemical formula 
C14H8O2 (figure 4). Anthraquinones are present in many plant extracts such as Rheum 
officinale, Aloe barbadensis, Rhamnus frangula, Rhamnus purshianus, Cassia 
angustifolia, Hypericum perforatum, and Polygonum genera (22, 28). It has been 
previously described that emodin, an anthraquinone derivative, specifically inhibits the 
nuclease activity of the HSV-1 alkaline nuclease, UL12 (22). It has also been reported 
that emodin demonstrated antiviral activity not only against herpes simplex virus type 1 
but also herpes simplex virus type 2 both in vitro and in vivo (29). 
Further, it has also been described that anthraquinone derivatives have antiviral 
activity against CMV (24). Several anthraquinone derivatives showed activity against 
CMV, including emodin, atanyl Blue PRL, acid blue 40, and alizarin violet R; however, 
their mechanism of anti-CMV activity has not been explored (23, 24). These findings 
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suggest that anthraquinone derivatives could be used as alternative antiviral agents 
against CMV. Moreover, since alkaline nucleases are highly conserved throughout the 
herpesvirus family, it is important to determine if anthraquinone derivatives act to inhibit 
CMV through inhibition of UL98 alkaline nuclease (50). 
 
2. Results 
To explore the antiviral activity of emodin, atanyl blue PRL, acid blue 40, and 
alizarin violet R, the same luciferase-based assay was used as in the previous section 
except a range of concentrations of the test compounds were tested. 
To explore the cytotoxicity of emodin, atanyl blue PRL, acid blue 40, and alizarin 
violet R, 96-well plates containing monolayers of MRC-5 cells were incubated with 
dilutions of the test compounds in 200 µl MEM in a 96-well format along with triplicates 
of no drug and no cell controls. 
After incubation for 5 days, 100 µl of supernatants were removed and 100 µl 
CellTiter-Glo assay reagent was added to each well. The luciferase signal is proportional 
to ATP present in the cell cultures, which reflects the number of viable cells. 
Luminescence was measured and the median toxic dose  (TD50) of the compounds was 
determined. 
Figure 9 shows the antiviral activity and toxicity of emodin. Emodin was used at 
concentrations of 0.24 µM to 250 µM and the nonlinear regression curve showed 
antiviral activity with an IC50 of 4.9 µΜ and cytotoxicity with a TC50 of 9.2 µM. The 
cytotoxicity is approximately two-fold higher than the antiviral activity. Figure 10 shows 
the antiviral activity for atanyl blue PRL, acid blue 40, and alizarin violet R. These 
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compounds were used at concentrations of 1.03 µM to 250 µM. The nonlinear regression 
curve showed antiviral activity of acid blue 40, atanyl blue PRL, and alizarin violet R to 
have an IC50 of 266 µM, 6.3 µM, and 238 µM respectively. Figure 11 shows the 
cytotoxicity of acid blue 40, atanyl blue PRL, and alizarin violet R. These compounds 
were used at concentrations of 8.23 µM to 2000 µM. The nonlinear regression curve 
showed cytotoxicity of acid blue 40, atanyl blue PRL, and alizarin violet R to have a 
TD50 of 231 µM, 216 µM, and 342 µM, respectively. Acid blue 40 and alizarin violet R 
inhibited CMV only at high concentrations; however, most of their apparent activity 
appears to be due to cytotoxicity. Lastly, figure 12 shows the antiviral activity and 
cytotoxicity of atanyl blue PRL side-by-side. Atanyl blue PRL, exhibited anti-CMV 
activity at an IC50 of 6.3 µΜ  with low cytotoxicity with a TD50 of 216 µΜ. Table 1 
summarizes the antiviral and cytotoxicity data. 
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Figure 9: Luciferase-based antiviral activity and cytotoxicity of emodin. For antiviral 
activity, confluent MRC-5 monolayers in 96-well plates were infected with RC2626 
(MOI = 0.03) and incubated for 5 days in the presence of emodin at concentrations of 
0.24 µM to 250 µM. Supernatants were transferred to another 96-well plate with MRC-5 
monolayers, incubated for 24 hours, and luciferase activity was measured. For 
cytotoxicity, 96-well plates containing uninfected confluent monolayers of MRC-5 cells 
were incubated with emodin at concentrations of 0.24 µM to 250 µM. After incubation 
for 5 days, cell viability was measured using CellTiter-Glo assay reagent. 
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Figure 10: Luciferase-based antiviral activity of acid blue 40, atanyl blue PRL, and 
alizarin violet R. Confluent MRC-5 monolayers in 96-well plates were infected with 
RC2626 (MOI = 0.03) and incubated for 5 days in the presence of acid blue 40, atanyl 
blue PRL, and alizarin violet R at a concentration of 0.24 µM to 250 µM. Supernatants 
were transferred to another 96-well plate with MRC-5 monolayers, incubated for 24 
hours, and luciferase activity was measured. 
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Figure 11: Luciferase-based cytotoxicity of acid blue 40, atanyl blue PRL, and 
alizarin violet R. 96-well plates containing uninfected confluent monolayers of MRC-5 
cells were incubated with acid blue 40, atanyl blue PRL, and alizarin violet R at 
concentrations of 8.23 µM to 2000 µM. After incubation for 5 days, cell viability was 
measured using CellTiter-Glo assay reagent. 
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Figure 12: Luciferase-based antiviral activity and cytotoxicity of atanyl blue PRL. 
For antiviral activity, confluent MRC-5 monolayers in 96-well plates were infected with 
RC2626 (MOI = 0.03) and incubated for 5 days in the presence of atanyl blue PRL at 
concentrations of 0.24 µM to 250 µM. Supernatants were transferred to another 96-well 
plate with MRC-5 monolayers, incubated for 24 hours, and luciferase activity was 
measured. For cytotoxicity, 96-well plates containing uninfected confluent monolayers of 
MRC-5 cells were incubated with atanyl blue PRL at concentrations of 8.23 µM to 2000 
µM. After incubation for 5 days, cell viability was measured using CellTiter-Glo assay 
reagent. 
 
 
 
 
 
-1 0 1 2 3
0
20
40
60
80
100
Log Atanyl Blue PRL Concentration (µM)
%
 M
ax
im
um
 L
um
in
es
ce
nc
e
Antiviral Activity
IC50 = 215.8 µM
IC50 = 6.329 µM
Toxicity
	  
	  
	   42 
 
 
 
 
 
 
Anthraquinone Compound Antiviral Activity (IC50) Cytotoxicity (TD50) 
Emodin 4.9 µM 9.2 µM 
Acid Blue 40 266 µM 231 µM 
Atanyl Blue PRL 6.3 µM 216 µM 
Alizarin Violet R 238 µM 342 µM 
 
Table 1: Summary of results from luciferase-based antiviral activity and cytotoxicity 
assays. Four anthraquinones that were evaluated are shown.  
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3. Conclusion 
Emodin showed antiviral activity with an IC50 of 4.9 µΜ and cytotoxicity with a 
TD50 value of 9.2 µM. Since the cytotoxicity is approximately two-fold higher than the 
antiviral activity, it suggests that emodin may act non-specifically. Because the antiviral 
activity and cytotoxicity of emodin were similar, it will not serve as a good compound to 
investigate further. The antiviral activities of acid blue 40, atanyl blue PRL, and alizarin 
violet R were found to have an IC50 values of 266 µM, 6.3 µM, and 238 µM respectively. 
The cytotoxicities of acid blue 40, atanyl blue PRL, and alizarin violet R to have TD50 
values of 231 µM, 216 µM, and 342 µM, respectively. Acid blue 40 and alizarin violet R 
exhibited anti-CMV activities only at high concentrations nearly matching their cytotoxic 
levels. Thus, most of their apparent antiviral activity may be due to cytotoxicity. Atanyl 
blue PRL exhibited anti-CMV activity at an IC50 of 6.3 µΜ and cytotoxicity with a TD50 
of 216 µΜ; a difference of approximately 1.5 logs between cytotoxicity and antiviral 
activity. Since atanyl blue PRL displayed anti-CMV activity with low cytotoxicity, the 
antiviral activity appears to be specific. Therefore, atanyl blue PRL is a useful compound 
to investigate further and characterize the mechanism of action.  
 
C. Evaluation of Atanyl Blue PRL 
1. Introduction 
It has been reported that atanyl blue PRL has a anti-CMV activity with an IC50 of 
7 µΜ and a TD50 value of 275 µΜ (31). Our data indicates similar results that the 
anthraquinone derivative, atanyl blue PRL, shows anti-CMV activity (IC50 = 6.3 µΜ) 
with low cytotoxicity (TD50 = 216 µΜ). However, questions remain regarding the 
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mechanism of action of this compound. Characterization of atanyl blue PRL, including 
impact on gene expression, GFP expression, impact on viral cell entry, impact on viral 
spread, impact on infectivity, and time of addition studies should be informative. The 
related compound emodin has been proposed to inhibit HSV-1 replication through 
inhibition of the HSV alkaline nuclease UL12. It has been demonstrated that UL98 is an 
important CMV gene, so demonstration that atanyl blue PRL inhibits CMV through 
inhibition of UL98 alkaline nuclease would serve to validate UL98 as a novel antiviral 
target and provide a lead structure for structure-based drug discovery (50).  
 
2. Results 
To evaluate the effect of atanyl blue PRL on GFP expression, 96-well plates 
containing confluent monolayers of MRC-5 cells were infected with BADrUL131-Y4, a 
virus engineered to express GFP. Atanyl blue PRL dilutions were transferred to cells 
immediately after infection to produce final compound concentrations of 1.03 µM to 250 
µM. Photomicrographs of GFP fluorescence were taken and GFP fluorescence was 
measured every two days. 
Figure 13 shows photomicrographs of the effect of atanyl blue PRL on GFP 
expression. There is a marked reduction in GFP expression with the addition of atanyl 
blue PRL. There is a significant reduction in GFP expression at concentrations greater 
than 9.36 µM. Figure 14 shows the GFP-based dose response of atanyl blue PRL on day 
4. The IC50 was determined to be 6.2 µM, indicating a similar dose response as the 
luciferase-based antiviral effect.  
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To evaluate the effect of atanyl blue PRL on viral spread, 96-well plates 
containing confluent monolayers of MRC-5 cells were infected with BADrUL131-Y4 at 
1,000 pfu (MOI=0.1) and 100 pfu (MOI=0.01) per well. The atanyl blue PRL dilutions 
were transferred to cells immediately after virus to produce final compound 
concentrations of 1.03 µM to 250 µM. Photomicrographs were taken and GFP 
fluorescence was measured every two days.  
Using the photomicrographs from the 100 pfu per well infection, a single infected 
cell was examined over time for viral spread and growth to neighboring cells. 
Photomicrographs were organized by day and concentration of compound. Figure 15 
shows photomicrographs of the effect of atanyl blue PRL on viral spread. Atanyl blue 
PRL was used at concentrations of 1.03 µM to 250 µM, however, no inhibitor and atanyl 
blue PRL at 9.26 µM are shown for day 6, 8, 10, and 12. It can be seen that there is a 
marked inhibition in viral spread as the days progress with the addition of atanyl blue 
PRL compared to no inhibitor.  
The GFP fluorescence RLUs were quantified, normalized, and fitted to a 
nonlinear regression curve to determine the IC50 of atanyl blue PRL inhibition. Figure 16 
shows the GFP-based dose response of atanyl blue PRL. The IC50 was determined to be 
6.3 µM on day 20, indicating a similar dose response with viral spread as the luciferase-
based antiviral effect.  
To assess the effect of atanyl blue PRL on the infectivity of CMV virus, 96-well 
plates containing confluent monolayers of MRC-5 cells were infected with BADrUL131-
Y4 at a dilution estimated to result in infection of only approximately 75% of wells. 
Atanyl blue PRL dilutions were transferred to infected cells with 32 replicates wells for 
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Figure 13: Photomicrographs of the effect of atanyl blue PRL on GFP expression. 
96-well plates containing confluent monolayers of MRC-5 cells were infected with 
BADrUL131-Y4 at an MOI of 1. Atanyl blue PRL dilutions were added to cell at 
concentrations of 1.03 µM to 250 µM. Photomicrographs shown were taken on day 2 and 
day 4 post infection. 
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Figure 14: Dose response of atanyl blue PRL. 96-well plates containing confluent 
monolayers of MRC-5 cells were infected with BADrUL131-Y4 at an MOI of 1. Atanyl 
blue PRL dilutions were transferred to cells immediately after virus to produce final 
compound concentrations of 1.03 µM to 250 µM. RLU’s of GFP fluorescence were 
measured four days post infection and normalized to percent maximum fluorescence. The 
data was normalized by converting RLU’s to “percent maximum fluorescence” for each 
experiment.  
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Figure 15: Photomicrographs of the effect of atanyl blue PRL on viral spread. 96-
well plates containing confluent monolayers of MRC-5 cells were infected with 
BADrUL131-Y4 at 100 pfu per well with or without 9.26 µM atanyl blue PRL. GFP-
positive cells were marked on day 6 post infection and the same region of the culture was 
photographed at two-day intervals.  
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each concentration to produce final drug concentrations of 3.09 µM to 250 µM. 32 wells 
of no inhibitor control were also included on the plate. After incubation for 14 days, each 
of the six sets of 32 wells was scored for the presence or lack of green fluorescence. The 
presence of fluorescence indicated a positive, virus-infected, well. The number of 
positive wells out of 32 was converted to “percent GFP positive wells” for each 
compound dilution and was fitted to a non-linear regression curve and the IC50 of the 
compound was determined. 
Figure 17 shows the effect of atanyl blue PRL on infectivity of CMV. Atanyl blue 
PRL was used at concentrations of 3.09 µM to 250 µM. It can be seen that as the 
concentration of atanyl blue PRL increases, there is a reduction in the percent of GFP 
positive wells. The results suggest that atanyl blue PRL lowers the infectivity of the virus, 
and may cause infected cells to become abortive and unable to produce progeny virus that 
can infect other cells. The percent GFP-positive wells were normalized and were fitted to 
a nonlinear regression curve to determine the IC50 of atanyl blue PRL. The IC50 was 
determined to be 7.1 µM, indicating a similar dose response as the luciferase-based 
spread, and GFP-expression assays.  
To study the effect of time of addition of atanyl blue PRL after infection, 96-well 
plates containing confluent monolayers of MRC-5 cells were infected with RC2626 virus 
(MOI=0.03). Atanyl blue PRL was prepared at a concentration of 27.8 µM in 200 µl 
MEM and added in triplicates at 0 hours, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 
72 hours, 96 hours, and 120 hours post infection.  Triplicates of ganciclovir (as an early 
acting control), BAY 38-4766 (as a late acting control), no drug, and no virus were also 
included on the plate. To determine if preincubation of the compound with the virus has  
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Figure 16: Dose response of atanyl blue PRL (day 20). 96-well plates containing 
confluent monolayers of MRC-5 cells were infected with BADrUL131-Y4 at 1,000 pfu 
per well (MOI=0.1). Atanyl blue PRL dilutions were transferred to cells immediately 
after virus to produce final compound concentrations of 1.03 µM to 250 µM. RLU’s of 
GFP fluorescence were measured every two days. The data was normalized by 
converting RLU’s to “percent maximum fluorescence” for each experiment.  
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Figure 17: Effect of atanyl blue PRL on infectivity of CMV. 96-well plates 
containing confluent monolayers of MRC-5 cells were infected with BADrUL131-Y4. 
Each atanyl blue PRL dilution was added to 32 replicate wells at concentrations of 3.09 
µM to 250 µM. After incubation for 14 days, wells were scored for the presence or lack 
of green fluorescence. The number of positive wells out of 32 was converted to “percent 
GFP positive wells” and was fitted to a non-linear regression curve and the IC50 of the 
compounds was determined. 
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an effect, triplicate samples of RC2626 (MOI=0.30) were incubated with 27.8 µM atanyl 
blue PRL for 1 hour followed by 10-fold dilution in culture media before addition to 
cells. After incubation for 5 days, 50 µl supernatants from the 96-well plate were 
transferred to another 96-well plate containing confluent MRC-5 monolayers. After 24 
hours the luciferase activity was measured in relative light units (RLU’s). The data were 
normalized by converting RLU’s to “percent maximum luminescence” for each 
experiment. In order to visualize the effect of the compound, percent maximum 
luminescence as a function of time, was plotted. 
Figure 18 shows the effect of time of addition of atanyl blue PRL post infection. 
Atanyl blue PRL was used at concentrations of 27.8 µM. In panel A of figure 18, atanyl 
blue PRL was added 0, 24, 48, 72, 96, and 120 hours post infection. The results indicate 
that atanyl blue PRL is only effective if added before 24 hours post infection. Ganciclovir 
is only effective if added before 72 hours and BAY 38-4766 is ineffective if added after 
72 hours. In panel B of figure 18, atanyl blue PRL was added 0, 1, 6, 12, 24, and 48 hours 
post infection. The results indicate that atanyl blue PRL is most effective if added before 
6 hours post infection, and ineffective if added after 24 hours post infection. This data 
suggests that atanyl blue PRL is an early acting compound. Pretreatment had no effect, 
suggesting that atanyl blue PRL does not interact with or modify the virion to alter 
attachment or entry of virus into cells or that inhibition is reversible.   
In order to analyze the effect of atanyl blue PRL on immediate early, early, and 
late gene expression, western immunoblot analysis was performed. Confluent MRC-5 
cells were infected with BadrUL131-Y4 at 8x10e5 pfu/flask (MOI=0.8). Compounds 
were added immediately after infection and cells were harvested along with untreated  
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Figure 18: Effect of time of addition of atanyl blue PRL post infection. 96-well plates 
containing confluent monolayers of MRC-5 cells were infected with RC2626 virus 
(MOI=0.03). In panel (A), atanyl blue PRL, GCV, or BAY 38-4766 were used at final 
concentrations of 27.8 µM, 10 µM, and 8 µM respectively and added at 0, 24, 48, 72, 96, 
or 120 hours post infection. In panel (B) atanyl blue PRL was added at 0, 1, 6, 12, 24, or 
48 hours post infection. Preincubation of RC2626 with atanyl blue PRL for 1 hour 
followed by 10-fold dilution in culture media before addition to cells was added at 0 
hours. After incubation for 5 days, 50 µl supernatants from the 96-well plate were 
transferred to another 96-well plate containing confluent MRC-5 monolayers and 
luciferase activity was measured after 24 hours. 
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control cultures 24, 48, 72, and 96 hours after infection. Lysates were separated on 
polyacrylamide gels and separated proteins were transferred to nitrocellulose membranes. 
Specific antibodies were used to detect UL98, UL99, IE1/2, and glycoprotein B.  
 Figure 19 shows the photomicrographs of the GFP expression of the cultures 
before harvesting for western immunoblot analysis. Consistent with previous 
experiments, atanyl blue PRL completely blocked GFP expression, at early times, 
although some GFP expression occurred at later stages of infection. Figure 20 illustrates 
the results of western immunoblot analyses. The top panel probes immediate-early 
protein expression with IE 1/2 mAB810 antibody, the middle panel explores early protein 
expression with UL98 and UL99 antibodies, and the bottom panel explores late protein 
expression with glycoprotein B antibody. The results indicate that atanyl blue PRL 
completely blocks IE1/2 expression on days 1 and 2. Some IE1/2 expression is seen on 
day 3 and 4, however, it is significantly reduced when compared to the replicate without 
atanyl blue PRL. Similar results were seen for early protein expression. Atanyl blue PRL 
reduced UL98 and UL99 expression when compared to the replicates without the 
inhibitor added. Finally, for late protein expression, atanyl blue PRL reduced the levels of 
glycoprotein B on days 1, 2, 3, while little difference was observed by day 4. 
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Figure 19: Photomicrographs of GFP expression of BadrUL131-Y4 before harvest 
for western immunoblot analysis. With and without atanyl blue PRL for days 1, 2, 3, 
and 4 are shown.  
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Figure 20: Western immunoblot analysis of IE 1/2, UL99, UL98, and glycoprotein B. 
The top panel explores immediate-early, the middle panel explores early, and the bottom 
panel explores late protein expression. ‘U’ denotes uninfected cells, ‘I+I’ denotes 
infected cells with the inhibitor atanyl blue PRL at a concentration of 27.8 µM, and ‘I’ 
denotes infected cells with no inhibitor. On the left the dual color standard marker is 
shown and the right has the respective protein size for the marker.  
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3. Conclusion 
GFP expression is thought to occur early in the viral replication cycle. The results 
in figure 13 suggest that atanyl blue PRL significantly reduced GFP expression 
suggesting that atanyl blue PRL effects early gene expression. The spread assay (figure 
15) further suggests that atanyl blue PRL reduces the amount of viral spread with time.  
In addition the infectivity assay (figure 17) indicates that atanyl blue PRL lowers the 
infectivity of the virus, and causes infected cells to become abortive and unable to 
produce progeny virus that can infect other cells and become a plaque. These results are 
consistent with the time of addition studies (figure 18) indicating that atanyl blue PRL is 
only effective in the first 24 hours, is most potent if added in the first 12 hours and is not 
very effective if added after 12 hours. Moreover, it does not appear to interact with the 
virus to impair attachment and entry as pretreatment had no affect. Western immunoblot 
analysis of IE 1/2, UL99, UL98, and glycoprotein B were also consistent with these 
results. Immediate-early expression was essentially eliminated in days 1 and 2 and early 
and late gene expression was significantly reduced. The results of GFP expression, time 
of addition, and western immunoblot analysis all suggest that atanyl blue PRL is an early 
acting compound with a profound affect on immediate-early gene expression. The effects 
on early and late gene expression are likely indirect results of reduced IE1/2 levels, as 
interference with immediate-early expression is known to have these downstream effects.  
 Deborah Parris, our collaborator at Ohio State University, recently demonstrated 
that atanyl blue PRL inhibits the nuclease activity of UL98 with an IC50 of 5.7 (figure 
21). Consistent with this result, docking of atanyl blue PRL into the UL98 alkaline 
nuclease homology model (courtesy of our collaborators Hardik Parikh and Glenn 
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Kellogg) indicates that atanyl blue PRL is a good fit in the UL98 alkaline nuclease active 
site. These results further suggests that atanyl blue PRL may express anti-CMV activity 
by inhibiting the UL98 alkaline nuclease.  
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Figure 21: Inhibition of UL98 alkaline nuclease activity by atanyl blue PRL. UL98 
was expressed in E. Coli and purified. Exonuclease activity of purified UL98 was 
measured using a 14C-release assay (50).  Unpublished data courtesy of Deborah Parris. 
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Figure 22: Docking of Atanyl Blue PRL into the UL98 homology model. Figure 
courtesy of Hardik Parikh and Glenn Kellogg. 
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IV. DISCUSSION 
 
 
Cytomegalovirus, or CMV, belongs to the Herpesviridae family of viruses (1). 
The Herpesviridae family of viruses is a large family of double stranded DNA (120 to 235 kb) 
viruses. The genome is encased in an icosahedral capsid and an outer protein matrix layer known 
as tegument (9). The CMV genome is expressed temporally in a regulated cascade leading to 
synthesis of three categories of viral proteins: Immediate-early, early, and late. Immediate-early 
genes are the first viral genes to be expressed after a cell is infected and do not require the 
expression of other viral genes or protein expression. Immediate-early genes regulate the 
expression of early and late genes and the expression of early genes is dependent on the presence 
of immediate-early proteins. Transcription of immediate-early genes can occur in the absence of 
de novo protein synthesis and produces two regulatory proteins, IE1 and IE2, which play key 
roles in initiating and maintaining CMV gene regulation pathways to ‘jump-start’ the infection. 
CMV is a relatively common infection with seroprevalence of 60% or more in persons 
greater than 50 years of age. It is estimated that between 45 to 100% of women of reproductive 
age are seropositive for CMV. The portion of women who are seronegative for CMV are at risk 
of primary CMV infection during pregnancy and bear a risk of giving birth to babies who will 
suffer from CMV-related disabilities. Most people infected with CMV are asymptomatic; 
however after primary infection some may show mild fever or mononucleosis-like symptoms 
and the host will remain infected with CMV in the latent phase for life. For 
immunocompromised and immunosuppressed patients, CMV is a significant cause of mortality 
and morbidity and it is also an important cause of birth defects in newborns if acquired in utero. 
(39). CMV is a major cause of mortality and morbidity in patients undergoing stem cell and solid 
organ transplantation (40). CMV is the most frequent opportunistic pathogen in patients infected 
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with HIV. Upwards of 45% of patients with AIDS are afflicted with CMV disease at some point 
during the course of their AIDS disease. In the United States, 40,000 children or 1% of all live 
births are born with an active congenital CMV infection. However, only 8,000 or 20% of those 
births are symptomatic. CMV infection is the most common congenital infection and a major 
cause of morbidity and mortality among infants (7). Infection can occur in utero, perinatally, or 
after birth due to contact with secretions such as breast milk and saliva of a seropositive mother 
(18).  
Currently, there are inadequate therapies to combat CMV. With the exception of 
fomivirsen, all approved drugs target the viral DNA polymerase, so there is a likelihood of 
mutations in the DNA polymerase rendering those drugs ineffective. The drugs are also 
associated with significant renal and bone marrow toxicities (13). Furthermore, due to their 
potential toxicities, none are approved for use during pregnancy.  This led to our interest in 
investigating novel antiviral targets. One such target, UL98, is attractive because although UL98 
null mutants are viable, viral replication in the absence of UL98 is reduced by up to 1,000-fold, 
indicting UL98 is an important though not essential CMV gene (50). Relevant to our interest in 
CMV UL98 as a potential antiviral target, it was previously described that emodin, an 
anthraquinone, specifically inhibits the HSV-1 alkaline nuclease, UL12, and that emodin and 
several related anthraquinones also inhibit replication of CMV. Due to the need for CMV 
antivirals with alternative targets of action and lower toxicity, investigation of UL98 may 
provide a novel target for the development of new CMV antivirals. Further, anthraquinone or 
anthraquinone derivatives represent a novel class of anti-herpesvirals.  If confirmed to act 
through inhibition of viral alkaline nucleases, they could serve as lead structures for structure-
based drug discovery. 
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 Our collaborators were able to use the amino acid sequence of CMV UL98 alkaline 
nuclease and the crystal structure KSHV-SOX protein as a template structure to model and 
identify the active sites of CMV UL98 (50). In order to find potential CMV UL98 inhibitors, this 
homology model was used to perform a virtual screening of the National Cancer Institute Open 
database of approximately 250,000 compounds. Those potential inhibitors were then docked, in 
silico, to the CMV UL98 model, and the 15 compounds deemed most likely to inhibit UL98 
activity were selected (figure 7). Surprisingly, based on the results of the luciferase-based assay 
for anti-CMV activity, none of these compounds showed any substantial antiviral activity (figure 
8).  This could be due to inaccuracies in the homology model. A model based on the crystal 
structure of CMV UL98 instead of KSHV-SOX would be preferable. It is also possible that the 
virtual screening algorithm that was used may have missed potential inhibitors with good activity 
against UL98.  Much larger databases of compound structures are available and they should be 
screened in order to find additional potential UL98 inhibitors. Finally, it is possible that some of 
the selected compounds are able to inhibit UL98 enzymatic activity but were unable cross the 
cell membrane and for this reason exhibited no anti-CMV activity in our assay. Our collaborator, 
Dr. Parris, plans to address this question by determining the ability of these compounds to inhibit 
the nuclease activity of UL98 using in vitro, cell-free assays.   
 Given the evidence that emodin inhibits HSV-1 and HSV-2 replication and interferes 
with the nuclease activity of HSV-1 UL12, we investigated emodin and other anthraquinones 
that had been previously reported to have anti-CMV activity. Emodin showed anti-CMV activity 
with an IC50 of 4.9 µΜ and cytotoxicity with a TD50 of 9.2 µM. These results are consistent with 
the those of Barnard et al. (1992), who reported an IC50 of 4.1 µΜ and TD50 of 9.6 µM. This 
rendered the antiviral effect almost indistinguishable from cytotoxicity and suggests that emodin 
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may act non-specifically. This was, however, inconsistent with the findings of Xiong et al. 
(2011), who observed anti-HSV activity of emodin with minimal toxicity. There is a possibility 
that this may be due the fact that emodin was extracted from different plants. The emodin used in 
our study was extracted from frangula bark, whereas Xiong et al. used emodin extracted from 
Rheum tanguticum, Chinese rhubarb. It is also possible that our emodin contained impurities that 
increased its toxicity. To address this concern a sample of the emodin used in our studies was 
evaluated by Ultra Performance Liquid Chromatography (UPLC) and found to be >99% pure.  
While a small amount of highly toxic contaminant cannot be ruled out, it appears from this result 
that the emodin used in our studies was not poor quality.   
 Acid blue 40, alizarin violet R, and atanyl blue PRL showed anti-CMV activity with 
IC50s of 266 µΜ,  238 µM, and 6.3 µM, respectively, and cytotoxicities with TD50s of 231 µM, 
342 µM, and 216 µM, respectively. For acid blue 40 and alizarin violet R, any antiviral activity 
shown by these compounds is likely due to non-specific cytotoxicity; hence, these compounds 
did not exhibit any compelling antiviral activity. These results for acid blue 40 and alizarin violet 
R are inconsistent with those of Barnard et al. (1995), who reported CMV-inhibiting IC50s of 10 
µΜ for both acid blue 40 and alizarin violet R. It is possible that these inconsistencies relate to 
poor solubility of these compounds. Barnard et al. used 0.001% tween-80 with 0.25% ethanol, 
which may have allowed for better solubility of the compounds. Additionally, it is possible that 
the DMSO used to prepare stock solutions for our studies may have interacted with these two 
compounds and rendered them ineffective. The cytotoxicities for these compounds, however, are 
relatively consistent with those of Barnard et al. (1995), who reported a TD50 of 380 µM for acid 
blue 40 and a TD50 of 300 µM for alizarin violet R. Further, our results for atanyl blue PRL are 
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consistent with the results of by Barnard et al. (1995), who reported an IC50 of 7.0 µΜ and TD50 
of 275 µM. Due to these results, atanyl blue PRL was selected for further study. 
 Atanyl blue PRL significantly reduced GFP expression (figure 13), suggesting that atanyl 
blue PRL inhibits early gene expression. The spread assay (figure 15) further suggests that atanyl 
blue PRL reduces the amount of viral spread with time. In addition, the infectivity assay (figure 
17) indicates that atanyl blue PRL lowers the infectivity of the virus and causes infected cells to 
become abortively infected. These results are also consistent with the time of addition studies 
that indicate that atanyl blue PRL is only effective when added early and virtually ineffective if 
added after 24 hours post infection. Atanyl blue PRL does not appear to modify the infectivity of 
free virus as pretreatment of free virus with the compound had no inhibitory effect. It is also 
unlikely that atanyl blue PRL interferes with viral attachment or entry since it was still highly 
inhibitory when added at 6 hours post infection, a time when entry has been completed. Further, 
western immunoblot analysis (figure 20) indicates that IE expression is largely eliminated by 
atanyl blue PRL and early and late expression is significantly reduced, most likely due to 
downstream affects of reduced IE protein levels. These findings are consistent with the previous 
results indicating that atanyl blue PRL is an early acting compound with an extensive affect on 
immediate-early gene expression.   
 Atanyl blue PRL was also found to inhibit UL98 alkaline nuclease exonuclease activity 
with an IC50 of 5.7 µM (figure 21), and atanyl blue PRL does appear to have a good fit into the 
homology model of CMV UL98 (figure 22). Hsiang and Ho (2008) found that the anthraquinone 
emodin inhibits HSV-1 alkaline nuclease UL12 and reduces viral yields, although it remains to 
be demonstrated that the mechanism of action of emodin’s anti-HSV activity involves inhibition 
of UL12. Our studies show results that are very consistent with that of Hsiang and Ho. We found 
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that the related anthraquinone atanyl blue PRL inhibits the CMV alkaline nuclease, UL98, and 
also has anti-CMV activity. Since alkaline nucleases are highly conserved throughout the 
Herpesvirus family, this result was hypothesized and expected. 
 Given that atanyl blue PRL inhibits CMV replication and also inhibits the CMV alkaline 
nuclease, UL98, it is possible that its mechanism of CMV inhibition involves inhibition of UL98. 
However, the exact function of UL98 and when it is expressed are not fully known. Our current 
understanding of herpesvirus alkaline nucleases suggests that they are somehow involved in 
repair of viral replicative intermediate DNA prior to DNA packaging – events that occur 
relatively late in the replication cycle. If atanyl blue PRL inhibits CMV replication through 
inhibition of UL98, then our characterization of the impact of atanyl blue PRL on the CMV 
replication cycle suggests that UL98 may be important very early after infection. How UL98 
might be important for IE gene expression is a matter of speculation. It is possible that UL98 is 
present in the virion particle, or is expressed de novo very early after infection, and has some 
function that promotes IE gene expression. For example, its presence in the virion might promote 
release of viral DNA from the capsid, circularization of viral DNA after release into the nucleus, 
or somehow impact DNA translocation to nuclear sites of active transcription (perhaps by 
degrading host DNA?). In addition, while UL98 clearly has DNase activity, it has not been 
evaluated for RNase activity.  The alkaline nucleases of Epstein-Barr virus and KSHV have been 
shown to have both DNase and RNase activities and have been proposed to be analogous to 
HSV-1 virion host shut-off protein, a virion-associated nonspecific RNase that shuts off host 
protein synthesis by rapidly degrading cellular mRNAs immediately after virus entry (30, 31, 
49). It is certainly conceivable that the absence of such an activity might reduce the efficiency 
with which viral immediate early proteins are expressed.  The added corollary to the assumption 
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that the anti-CMV activity of atanyl blue PRL is linked to inhibition of UL98 is that UL98 
activity is therefore not important for the processes of DNA synthesis or DNA packaging that 
occur at later times of infection (e.g., atanyl blue PRL had no impact on CMV replication when 
added 24 hours after infection, a time well before DNA replication and packaging begins). 
 Alternatively, it is possible that atanyl blue PRL could inhibit UL98 and also have some 
other unrelated inhibitory activity that results in a to block immediate-early gene expression.  
Thus, inhibition of UL98 could just be coincidental and atanyl blue PRL uses some other as yet 
undetermined mechanism for antiviral activity.  One trivial explanation is that atanyl blue PRL, 
due to its relatively planar anthraquinone structure, may nonspecifically impair transcription by 
interchelation into DNA. This explanation would seem highly unlikely given that addition of 
atanyl blue PRL at 24 hours post infection had no impact on viral replication. At this time early 
genes are just beginning to be expressed and late genes are not yet activated. Moreover, an 
interchelator would also be expected to inhibit viral DNA synthesis, which is only just starting at 
24 hours post infection. Thus, non-specific inhibition of RNA transcription or DNA synthesis at 
24 hours post infection or later would be expected to cause major reductions in virus yield.  
 Future studies into atanyl blue PRL will involve creating atanyl blue PRL-resistant 
viruses, mapping the mutations responsible for resistance, and determining if those mutations lie 
in UL98. If mutations that confer resistance are identified in UL98 then it is quite conclusive that 
atanyl blue PRL is specifically affecting CMV replication through inhibition of UL98. Also, 
UL98 null mutants could be used and examined for resistance to atanyl blue PRL. If there is no 
change in the growth of the mutants, this it would suggest that UL98 is the only target. However, 
if there is further attenuation of viral growth, then there must be another mechanism that atanyl 
blue PRL uses to target some other important viral function.  
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Formal confirmation that atanyl blue PRL acts by inhibiting UL98 is important for two 
reasons.  First, this would establish that UL98 activity is critically important only at very early 
times of infection. As discussed above, this would be paradigm-shifting for our understanding of 
how alkaline nucleases function, at least in the context of CMV replication. Second, atanyl blue 
PRL could serve as a lead structure for further structure-function studies to derive more active 
inhibitors that would presumably have greater antiviral potency. Finally, if it can be 
demonstrated that atanyl blue PRL has anti-CMV activity against animal CMVs such as murine 
CMV, guinea pig CMV, or rhesus CMV, then animal studies of antiviral efficacy could be 
considered.  
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